revolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.